232 related articles for article (PubMed ID: 31541382)
1. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies.
Jeon J; Kim SE; Lee DY; Choi D
Breast Cancer Res Treat; 2020 Jan; 179(1):125-130. PubMed ID: 31541382
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.
Lee M; Piao J; Jeon MJ
Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174
[TBL] [Abstract][Full Text] [Related]
3. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Romero SA; Young K; Hickey M; Su HI
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
[TBL] [Abstract][Full Text] [Related]
4. [Uterine abnormalities in non menopausal women who received tamoxifen for breast cancer adjuvant therapy].
d'Arailh AS; Michy T; Pioud R; Dravet F; Classe JM
Gynecol Obstet Fertil; 2007 Dec; 35(12):1215-9. PubMed ID: 18035581
[TBL] [Abstract][Full Text] [Related]
5. [Tamoxifen and endometrial pathology].
Negoiţă M; Terinte C; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1114-7. PubMed ID: 21500468
[TBL] [Abstract][Full Text] [Related]
6. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings.
Hann LE; Giess CS; Bach AM; Tao Y; Baum HJ; Barakat RR
AJR Am J Roentgenol; 1997 Mar; 168(3):657-61. PubMed ID: 9057510
[TBL] [Abstract][Full Text] [Related]
7. [MR Imaging of the pelvis in the diagnosis of the endometrium in breast cancer patients in tamoxifen therapy].
Hauth E; Libera H; Kimmig R; Forsting M
Rofo; 2006 Mar; 178(3):316-23. PubMed ID: 16508840
[TBL] [Abstract][Full Text] [Related]
8. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
9. Uterine side effects of tamoxifen: a need for systematic pretreatment screening.
Berlière M; Charles A; Galant C; Donnez J
Obstet Gynecol; 1998 Jan; 91(1):40-4. PubMed ID: 9464718
[TBL] [Abstract][Full Text] [Related]
10. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer.
Deligdisch L; Kalir T; Cohen CJ; de Latour M; Le Bouedec G; Penault-Llorca F
Gynecol Oncol; 2000 Aug; 78(2):181-6. PubMed ID: 10926800
[TBL] [Abstract][Full Text] [Related]
11. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
[TBL] [Abstract][Full Text] [Related]
12. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.
Cohen I; Perel E; Flex D; Tepper R; Altaras MM; Cordoba M; Beyth Y
J Clin Pathol; 1999 Apr; 52(4):278-82. PubMed ID: 10474520
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen use as a malignancy risk factor in postmenopausal women with endometrial polyps.
Yela DA; Ikejiri TA; Machado CR; Mutta D; Benetti-Pinto CL
Menopause; 2019 Aug; 26(8):863-866. PubMed ID: 30969185
[TBL] [Abstract][Full Text] [Related]
14. Endometrial tubal metaplasia in a young puerperal woman after breast cancer.
Di Benedetto L; Giovanale V; Caserta D
Int J Clin Exp Pathol; 2015; 8(6):7610-3. PubMed ID: 26261678
[TBL] [Abstract][Full Text] [Related]
15. Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen.
Marchesoni D; Driul L; Fabiani G; Di Loreto C; Cataldi P; Mozzanega B
Int J Gynaecol Obstet; 2001 Dec; 75(3):257-62. PubMed ID: 11728486
[TBL] [Abstract][Full Text] [Related]
16. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients.
Cohen I; Altaras MM; Shapira J; Tepper R; Rosen DJ; Cordoba M; Zalel Y; Figer A; Yigael D; Beyth Y
Int J Gynecol Pathol; 1996 Apr; 15(2):152-7. PubMed ID: 8786205
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen.
Bornstein J; Auslender R; Pascal B; Gutterman E; Isakov D; Abramovici H
J Reprod Med; 1994 Sep; 39(9):674-8. PubMed ID: 7807477
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen and endometrial pathologies: a prospective study.
Seoud M; Shamseddine A; Khalil A; Salem Z; Saghir N; Bikhazi K; Bitar N; Azar G; Kaspar H
Gynecol Oncol; 1999 Oct; 75(1):15-9. PubMed ID: 10502419
[TBL] [Abstract][Full Text] [Related]
19. Hysteroscopically targeted biopsies compared with blind samplings in endometrial assessment of menopausal women taking tamoxifen for breast cancer.
Garuti G; Cellani F; Colonnelli M; Garzia D; Gonfiantini C; Luerti M
J Am Assoc Gynecol Laparosc; 2004 Feb; 11(1):62-7. PubMed ID: 15104834
[TBL] [Abstract][Full Text] [Related]
20. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring.
Vosse M; Renard F; Coibion M; Neven P; Nogaret JM; Hertens D
Eur J Obstet Gynecol Reprod Biol; 2002 Feb; 101(1):58-63. PubMed ID: 11803101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
